Neuren Pharmaceuticals Limited (NEU) - Research

$1.120

NEU General Information +

ASX Code NEU
Website http://www.neurenpharma.com
GICS Sub-Industry Pharmaceuticals
Market Cap ($M) 114
Current Price $1.120
Day High $1.140
Day Low $1.100
Last Close $1.120
Price Movement - ( No change )
Prices as at 16:40, 26 Jun 2019
+Security prices are delayed by at least 20 minutes and are indicative only.

NEU Company Overview

Business Description

Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders. NEU has two key drug products comprising NNZ-2566 and NNZ-2591. NEU has operations in New Zealand, Australia and the USA.

NEU Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2020 F 0.00 -4.60 0.00% 0.00 0.00 0.00% 0.0%
2019 F 0.00 -12.70 0.00% 0.00 0.00 0.00% 0.0%
2018 A 3.07 3.10 -11.40% 74.30 0.00 0.00% 0.0%

NEU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2018 A 2019 F 2020 F 2018 A 2019 F 2020 F 2018 A 2019 F 2020 F
Mayne Pharma Group (MYX) $760M -0.5645 -0.2404 0.7615 16.7247 22.0183 12.5000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals (NEU) $113M -0.1143 0.0000 0.0000 36.4516 0.0000 0.0000 0.00% 0.00% 0.00%
Starpharma (SPL) $515M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NEU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 1.00 0.00 4.66 0.00
Market 0.59 14.90 1.16 0.99
Sector 0.95 28.90 3.23 2.09

NEU Directors

Name Position Start Date
Dr Richard Spencer Treagus Executive Director, Executive Chairman 31 Jan 2013
Dr Trevor D Scott Non-Executive Director 5 Mar 2002
Ms Dianne Angus Non-Executive Director 1 Jul 2018
Dr Jenny Lee Harry Non-Executive Director 7 Jul 2018
Mr Patrick Davies Non-Executive Director 1 Jul 2018

NEU Management

Name Position
Jon Charles Pilcher Chief Financial Officer,Joint Company Secretary
Larry Glass Chief Science Officer
Nancy Jones Vice President, Clinical Development
James Shaw Vice President, Clinical Operations
Clive Blower Vice President, Product Development and Technical Affairs

NEU Substantial Shareholders

Holding Name
18,267,119 (17.94%) Langley Alexander Walker

NEU Calendar of Events

Date Event
24 April 2020 Report (Annual)
26 February 2020 Report (Prelim)
30 August 2019 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.